跳至主要内容
临床试验/NL-OMON47428
NL-OMON47428招募中不适用

Examining the pharmacokinetic and pharmacodynamic profile of biperiden - PK/PD biperiden

niversiteit Maastricht0 个研究点目标入组 42 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  • The participant has a body mass index of 18.5-30 kg/m2, inclusive, at medical screening.
  • The participant is aged 18 to 35 years, inclusive, at the time of informed consent.
  • The volunteer is healthy, i.e. absence of all exclusion criteria and had normal or corrected to normal static binocular acuity with or without correction.
  • The participant signs and dates a written informed consent form before the start of the experiments.
  • The participant has sufficient knowledge of the English language.

排除标准

  • The subject has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality which may impact the ability of the subject to participate or potentially confound the study results.
  • The volunteer has uncontrolled existing major psychiatric symptoms.
  • The participant has known hypersensitivity to any component of the formulation or biperiden or related compounds.
  • The subject has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the first visit or is unwilling to agree to abstain from alcohol from 24 hours prior to each test day and/or drugs throughout the study.
  • The participant has any sensory or motor deficits which could reasonably be expected to affect test performance.
  • Other exclusion criteria are smoking, excessive drinking (>20 glasses of alcohol containing beverages a week), pregnancy or lactation, use of medication other than oral contraceptives.

研究者

相似试验

Examining the pharmacokinetic and pharmacodynamic... | 临床试验